<code id='B11EE3C2EE'></code><style id='B11EE3C2EE'></style>
    • <acronym id='B11EE3C2EE'></acronym>
      <center id='B11EE3C2EE'><center id='B11EE3C2EE'><tfoot id='B11EE3C2EE'></tfoot></center><abbr id='B11EE3C2EE'><dir id='B11EE3C2EE'><tfoot id='B11EE3C2EE'></tfoot><noframes id='B11EE3C2EE'>

    • <optgroup id='B11EE3C2EE'><strike id='B11EE3C2EE'><sup id='B11EE3C2EE'></sup></strike><code id='B11EE3C2EE'></code></optgroup>
        1. <b id='B11EE3C2EE'><label id='B11EE3C2EE'><select id='B11EE3C2EE'><dt id='B11EE3C2EE'><span id='B11EE3C2EE'></span></dt></select></label></b><u id='B11EE3C2EE'></u>
          <i id='B11EE3C2EE'><strike id='B11EE3C2EE'><tt id='B11EE3C2EE'><pre id='B11EE3C2EE'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:entertainment    - browse:724
          3d heart myocarditis
          Adobe

          A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

          The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

          advertisement

          In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia